EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma

Yu-Zhe Cao, Jia-Yu Pan, Guang-Lei Zheng, Chao An, Meng-Xuan Zuo

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03872-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Yu-Zhe Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cance…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Infusions, Intra-Arterial, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: The goal of this study was to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with targeted therapy and PD-(L)1 blockade (triple therapy), either sequentially (SE) or simultaneously (SI), in the treatment of Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). APPROACH AND RESULTS: From January 1, 2018, to June 1, 2022, 575 patients with BCLC stage C HCC who underwent SE or SI triple therapy were retrospectively enrolled. Propensity score matching (PSM; 1:1) was performed to eliminate possible confounder imbalances across cohorts. We used the Kaplan-Meier method and a log-rank test to compare the overall survival (OS) and progression-free survival (PFS) rates between the SI and SE groups. The tumor response and the incidence of adverse events (AEs) were reported. After PSM, 182 patients in each of the two groups were matched. The median OS in the SI group was significantly longer than that in the SE group (28.8 vs. 16.1 months; P = 0.002), and the median PFS was significantly improved in the SI versus SE group (9.6 vs. 7.0 months; P = 0.01). The objective response rate based on the mRECIST was higher in the SI group (58% vs. 37%; P < 0.001). The total incidences of grade 3-4 AEs were 111/182 (60.9%) and 128/182 (70.3%) in the SE and SI groups, respectively. No grade 5 AEs were reported in either group. CONCLUSIONS: Simultaneous HAIC plus targeted therapy and PD-(L)1 blockade significantly improved outcomes compared to the sequential regimen in patients with BCLC stage C HCC, with no unexpected AEs. CLINICAL RELEVANCE STATEMENT: The patients who received hepatic arterial infusion chemotherapy combined with targeted therapy and PD-(L)1 blockade simultaneously have a better prognosis than those who received it sequentially.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsInfusions, Intra-ArterialAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedHepatic ArteryAdultImmune Checkpoint InhibitorsNeoplasm Staging

Stichwörter der Autor:innen

Hepatic arterial infusion chemotherapyHepatocellular carcinomaPD-(L)1 blockadeSequentially and simultaneouslyTargeted therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Ro…
  • State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China.
  • Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China.
  • State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China. anchao-1983@163.com.
  • Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China. anchao-1983@163.com.
  • State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China. zuomx@sysucc.org.cn.

Zitieren

APA

Cao, Y. Z., Pan, J. Y., Zheng, G. L., An, C., & Zuo, M. X. (2024). Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03872-6

Vancouver

Cao YZ, Pan JY, Zheng GL, An C, Zuo MX. Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03872-6

BibTeX
@article{Cao2024,
  author = {Cao, Yu-Zhe and Pan, Jia-Yu and Zheng, Guang-Lei and An, Chao and Zuo, Meng-Xuan},
  title = {Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03872-6}
}
Kostenlos starten →